title: Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA.
abstract: BACKGROUND
  Current HIV-1 antiretroviral therapy (ART) greatly reduces virus replication but does not significantly affect the viral reservoir. Raltegravir, a recently introduced integrase inhibitor, could, at least theoretically, reduce residual viremia in patients on ART and affect the viral reservoir size. The aim of this study was to assess whether switching therapy in treatment-experienced patients that were virally suppressed to a raltegravir-containing regimen reduces the size of the viral reservoir, and if such treatment leads to a change in levels of HIV 2-LTR circles in this patient group.
  
  
  METHODS
  14 ART experienced individuals with a suppressed viral load (<50 HIV-1 RNA copies/mL plasma) at baseline (for at least 2 months) were switched to a raltegravir-containing regimen. Blood samples were taken at baseline and at ≥2 timepoints up to 48±6 weeks. Levels of total HIV-1 DNA and 2-LTR circles in peripheral blood mononuclear cells (PBMCs) were measured using real-time PCR assays.
  
  
  RESULTS
  There was no significant change in HIV-1 total DNA levels over the study duration (p = 0.808), median slope 0.24 (conservative nonparametric 95% CI: -11.78, 26.23). Low levels of 2-LTR circles were detected in 2 patients. One had 16 copies/10(6) PBMCs at baseline and the other had 34 copies/10(6) PBMCs at week 51.
  
  
  CONCLUSIONS
  The switch to a raltegravir containing regimen was not associated with a significant change in HIV-1 total DNA levels in this cohort. There were no observed changes in the levels of HIV-1 2-LTR circles associated with raltegravir treatment initiation.
authors.affiliation: The Kirby Institute, University of New South Wales, Sydney, Australia. paulymlam@gmail.com
authors.forename: Yu Ming Paul
authors.initials: YM
authors.lastname: Lam
authors.forename: Kristin L
authors.initials: KL
authors.lastname: McBride
authors.forename: Janaki
authors.initials: J
authors.lastname: Amin
authors.forename: Damien V
authors.initials: DV
authors.lastname: Cordery
authors.forename: Anthony D
authors.initials: AD
authors.lastname: Kelleher
authors.forename: David A
authors.initials: DA
authors.lastname: Cooper
authors.forename: Kersten K
authors.initials: KK
authors.lastname: Koelsch
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000494:pharmacology; D015331:Cohort Studies; D004247:DNA / Q000378:metabolism; D017931:DNA Primers / Q000235:genetics; D004279:DNA, Viral / Q000235:genetics*; D015658:HIV Infections / Q000188:drug therapy; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000166:cytology; D008297:Male; D008875:Middle Aged; D011760:Pyrrolidinones / Q000494:pharmacology*; D000068898:Raltegravir Potassium; D060888:Real-Time Polymerase Chain Reaction / Q000379:methods; D020079:Terminal Repeat Sequences; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D017931:DNA Primers; D004279:DNA, Viral; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D004247:DNA